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Abstract
The inaugural European Network for Breast Development and
Cancer (ENBDC) meeting on ‘Methods in Mammary Gland
Development and Cancer’ was held in Weggis, Switzerland last
April. The goal was to discuss the details of techniques used to
study mammary gland biology and tumourigenesis. Highlights of
this meeting included the use of four-colour fluorescence for
protein co-localisation in tissue microarrays, genome analysis at
single cell resolution, technical issues in the isolation of normal and
tumour stem cells, and the use of mouse models and mammary
gland transplantations to elucidate gene function in mammary
development and to study drug resistance in breast cancer.
Introduction
There are several meetings devoted to breast cancer
research, some of which include talks on normal breast
development. In contrast, there is no meeting specifically
dedicated to discussing methods used in breast development
and cancer. A new group, the European Network for Breast
Development and Cancer (ENBDC), has initiated an annual
meeting specifically devoted to presenting and discussing
methods in the mammary gland field. The first meeting was
organised in Weggis, Switzerland last April. First-year
graduate students as well as novices in the field of breast
development and cancer were encouraged to attend. This
inaugural meeting encompassed discussions on breast
cancer histopathology, tumour-initiating cells, animal models
and normal breast stem cells.
Methods in human and mouse breast
pathology (Chair: Torsten Stein)
The first session included David Robertson from the
Breakthrough Breast Cancer Research Centre in London and
Dr Kim Jensen from Cambridge University. Robertson
presented the latest developments in multi-colour fluorescent
imaging using formalin-fixed paraffin-embedded (FFPE)
sections. FFPE archives around the world add up to a large
database of tumour samples, but standard staining using
chromogenic substrates has several limitations, especially the
inability to target multiple proteins simultaneously and the
limited intracellular resolution. Immunofluorescence poten-
tially provides increased resolution and allows a multi-colour
approach. However, FFPE material often displays a high level
of auto-fluorescence. Using an optimised protocol and
confocal laser microscopy, Robertson was able to drama-
tically reduce this background fluorescence, allowing the use
of four-colour fluorescence for cellular and intracellular co-
localisation studies on FFPE tissue microarrays [1]. His latest
protocols will be published on the ENBDC website [2].
Kim Jensen from Fiona Watt’s laboratory also presented work
on studying multiple genes in small samples. He has
developed a technique for full genome microarray analysis on
RNA amounts equivalent to that from a single cell using a
PCR-based amplification step. This allowed him to study
mRNA expression profiles of single flow sorted epidermal
stem cells. In this way, Lrig1 was identified as a marker for
epidermal stem cells that keeps these cells in a quiescent
state [3]. Jensen further showed that Lrig1-positive cells
define a distinct subpopulation in the hair follicle that can give
rise to all epidermal cell lineages, as well as to cells of the
sebaceous gland and the interfollicular epidermis [4]. This
powerful technique thus allows the study of the expression
profiles of very small numbers of cells, including from isolated
cap cells of the mammary terminal end bud or from very small
flow sorted mammary cell populations.
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Cancer stem/progenitor cells of the breast
(Chair: Rob Clarke)
In the second session, Dr John Stingl from the Cancer
Research UK Cambridge Research Institute spoke about the
detection and analysis of mammary gland stem and pro-
genitor cells. These cells are detected by their ability to
generate ductal-lobular outgrowths when transplanted into
immune-compatible mice and by their ability to generate
colonies in vitro. Stingl reviewed some limitations of these
assays, with particular emphasis on how variable they can be
with minor changes in protocol. He presented results from his
laboratory on how to minimize variability and increase the
efficiency of these assays. For example, the enzymatic disso-
ciation of mammary glands in growth factor-depleted versus
growth factor-rich media results in the differential yield of
mammary stem and progenitor cells, with stem cells pre-
ferring growth factor-depleted conditions and the progenitor
cells favouring growth factor-rich conditions. As well, the
detection frequency of stem cells can be increased approxi-
mately sixfold by the inclusion of Matrigel™ within the
transplant inoculum.
The second speaker, Dr Gabriela Dontu from King’s College,
University of London, talked about estrogen receptor (ER)
expression in stem and progenitor cells from normal and
malignant breast epithelium. Dontu proposed that no one
stem cell marker is useful for all breast cancers and that there
may be specific markers useful for different breast cancer
subtypes, of which there are at least five. For example,
aldehyde dehydrogenase expression determined by the
fluorescent substrate Aldefluor is useful for enriching stem
cells in normal and some malignant breast samples but is low
in cell lines and absent in many ER-positive cancers [5].
Dontu argued that researchers should beware of several
common misconceptions concerning cancer stem cells. In
reality, there are unlikely to be universal markers, the cancer
stem cell population may not be infrequent (up to 25% in
melanoma) [6], there will be genetic and phenotypic
heterogeneity within a tumour, not all tumours will be
hierarchical, and the cancer stem cell model is compatible
with, and not distinct from, the clonal evolution model.
Animal models for studying breast cancer
(Chair: Jos Jonkers)
In the third session, Dr Sven Rottenberg from the Nether-
lands Cancer Institute talked about drug responses and
therapy resistance in conditional mouse models of breast
cancer. Resistance to chemotherapy is a central unsolved
problem in breast cancer treatment, since most patients die
of disseminated tumours that are resistant to all forms of
therapy. To tackle clinically relevant mechanisms of drug
resistance, Rottenburg used the K14cre;Brca1F/F;p53F/F
mouse model for BRCA1-associated breast cancer [7], and
found acquired resistance to cytotoxic drugs (doxorubicin,
docetaxel) [8] and to the poly(ADP-ribose) polymerase
(PARP) inhibitor AZD2281, which induces synthetic lethality
in BRCA1-deficient tumours [9]. The only resistance mecha-
nism identified thus far is upregulation of the P-glycoprotein
multidrug efflux transporter. Although no resistance was
observed for cisplatin, tumours could not be eradicated and
consistently re-grew from small tumour remnants. These
remnants were not enriched in tumour-initiating cells, but
contained beta-galactosidase-positive and Ki-67-negative
cells, suggesting (therapy-induced) senescence or dormancy
as escape mechanisms.
The second speaker, Dr Vida Vafaizadeh from the Georg-
Speyer-Haus in Frankfurt am Main, Germany, investigated the
role of Stat5 in mammary gland development and tumouri-
genesis via ex vivo transduction of primary mammary
epithelial cells with lentiviral vectors encoding a Stat5-
specific short hairpin RNA (shStat5ab) or a constitutively
active Stat5 variant (cS5F). The transduced mammary epi-
thelial cells were transplantated into cleared fat pads to
reconstitute functional glandular epithelium. Downregulation
of Stat5 did not affect the outgrowth of primary ducts, but
resulted in thinner ducts, reduced side-branching and
impaired alveologenesis. Conversely, constitutive activation of
Stat5 caused hyperproliferation of epithelial cells, thickening
of the ducts and precocious alveolar development in
nulliparous mice, indicating that Stat5 activity regulates the
emergence of mature alveolar cells from luminal progenitors.
The persistent activation of Stat5 during the involution stage
prevents apoptosis of the epithelial cells and causes
formation of tumours that also express activated Stat3.
Studying normal mammary stem cells
(Chairs: Matthew Smalley and 
Mohamed Bentires-Alj)
In the final session, Dr Matthew Smalley from the Break-
through Breast Cancer Research Centre discussed the
preparation and flow cytometric analysis of primary mammary
epithelial cells, including stem cells. His group uses the
CD24, Sca1 and CD49f markers to isolate four lineages of
the mammary gland: basal stem cells, basal myoepithelial
cells, ER-positive luminal cells and ER-negative luminal cells
[10]. The critical steps for optimal isolation of the different
lineages and confirming the identity of the isolated
subpopulations were the topics of Smalley’s presentation. In
particular, he focussed on the validation of antibodies used
for flow cytometric cell separation. He argued that gating
based on controls in which one antibody is left out of the
staining cocktail (‘fluorescence minus one’ controls) are
critical. He also noted that different fluorochromes
conjugated to the same antibody clone may give different
flow cytometric patterns, as may different clones against the
same antigen. Hence, antibody titration to saturation must be
carried out for each new fluorochrome combination. Finally, to
assess the quality of the whole process, each population
isolated must be characterised by testing expression of cell-
type specific markers and in vitro and  in vivo functional
assays [10,11].The second speaker, Dr Marina Glukhova from the Institut
Curie in Paris, discussed the usefulness of the keratin 5 (K5)
promoter active in the basal cells from various stratified
epithelia for targeting transgenes to the basal cell layer of the
mammary epithelium. Glukhova’s lab crossed transgenic mice
expressing Cre recombinase under the control of the K5
promoter with mice presenting conditional alleles for β1
integrin gene (itgb1F/F). In virgin mutant mice, β1 integrin
was efficiently deleted from the basal cell layer, whereas
luminal cells remained β1 integrin-positive. The deletion of the
itgb1 gene completely abolished the regenerative potential of
the mammary epithelium, suggesting that β1 integrins are
essential for the maintenance of the functional stem cell
population [12]. Surprisingly, in pregnant mutant mice,
luminal cells in the alveoli stained negative for β1 integrin,
suggesting that they originated from K5-positive basal cells.
Further analysis showed that whereas wild-type basal cells
divide parallel to the basement membrane and their progeny
therefore remained in the basal layer, the orientation of basal
division was random in glands from K5cre;Itgb1F/F mice.
This led to cell fate changes explaining the presence of
progeny from the basal cells in the luminal layer. Further,
using the K5 promoter, this lab has obtained transgenic mice
presenting a constitutive activation of Wnt/β-catenin signal-
ling in basal mammary epithelial cells. These mice develop
hyperplastic mammary lesions presenting characteristics
similar to those of human breast basal-type carcinomas.
Conclusion
The meeting proved a very valuable forum for the
dissemination of ideas and experiences relating to commonly
used, but sometimes poorly understood, techniques in
mammary cell biology. Talks by speakers from outside the
mammary cell biology field also helped highlight, especially to
younger researchers, potential new avenues for exploration.
Planning is already beginning for the 2010 meeting, which, it
is hoped, will prove as stimulating as in 2009.
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